Heather A. Parsons, MPH, MD, is Program Director in Breast Oncology, the Maudslien Endowed Chair in Breast Cancer Precision Oncology Research, and Associate Professor in the Clinical Research Division at Fred Hutch Cancer Center and the Department of Medicine at the University of Washington. She is an Associate Member in the Cancer Program at the Broad Institute of MIT and Harvard. A nationally recognized expert in breast cancer and precision oncology, Dr. Parsons leads pioneering research in circulating tumor DNA (ctDNA) and liquid biopsy technologies, with a particular focus on minimal residual disease (MRD) detection and its clinical applications. Her work has shaped multiple clinical trials and translational studies aimed at improving outcomes for patients with HER2-positive and metastatic breast cancer. She serves in leadership roles across national research consortia and guideline committees, and her contributions have been widely published in high-impact journals.

Dr. Jazaeri is a Professor and the Vice Chair for Clinical Research in the Department of Gynecologic Oncology and Reproductive Medicine at the University of Texas MD Anderson Cancer Center.  He also serves as the Director of the Gynecologic Cancer Immunotherapy Program. In addition to novel immunotherapies for gynecologic cancers, his other areas of research interest include investigation of the minimal residual disease phase of ovarian cancer, and innovative clinical trial designs.

Dr. Jeffrey Gregg is Vice President of Medical Affairs at Foresight Diagnostics, where he focuses on medical affairs strategy, evidence generation, and medical education for ctDNA-based measurable residual disease (MRD) testing. He previously served as Professor of Pathology at UC Davis School of Medicine, where he also directed clinical pathology and molecular diagnostics programs. With more than 25 years of experience in oncology diagnostics, Dr. Gregg has held senior leadership roles at Biofidelity, Harbinger Health, Freenome, and Foundation Medicine. He has authored over 100 peer-reviewed publications in molecular diagnostics and precision oncology and is a frequent speaker at national and international oncology meetings.

Lauren C. Leiman, MBA is currently the Executive Director of the Blood Profiling Atlas in Cancer (BLOODPAC), a consortium focused on creating an open database for liquid biopsies to accelerate the development of safe and effective blood profiling diagnostic technologies for patient benefit.  Lauren received her undergraduate degree in communications from the University of Pennsylvania's Annenberg School. She also holds an MBA in international business from the University of North Carolina's Kenan-Flagler Business School and a master's degree in public relations and corporate communications from NYU. Through her work with BLOODPAC, Lauren has numerous publications many of which are in the liquid biopsy space.